We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Armando Anido has served as our Chairman and Chief Executive Officer(CEO) since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to Zynerba, Mr. Anido served as CEO of two publicly trade companies: NuPathe (NASDAQ: PATH), which was acquired by Teva Pharmaceuticals in February 2014, where he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine; and Auxilium Pharmaceuticals (NASDAQ: AUXL), where under his leadership, sales grew from $42 million in 2005 to more than $260 million in 2011 and market capitalization increased from $200 million to more than $900 million. He is currently a member of the Board of Directors of PA Bio, and he was a member of the Board of Directors of Adolor until it was sold to Cubist in December 2011. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.
This speaker's sessions: